Sodium thiosulfate is a Small Molecule owned by Fennec Pharmaceuticals, and is involved in 4 clinical trials, of which 2 were completed, and 2 are ongoing.

Sodium thiosulfate inactivates the metabolic by-products of cisplatin circulating in the plasma, which appear to be responsible for hearing loss. Because STS remains only in the plasma and does not distribute into the cells where cisplatin produces its anticancer effects, there appears to be no effect on the anticancer effectiveness of cisplatin. Further, the anticancer activity of cisplatin occurs during the first two hours after administration when the free (unbound) cisplatin distributes into the cancer cells. STS inactivates the residual activity of these metabolites in the plasma, neutralizing their ability to cause hearing loss.

The revenue for Sodium thiosulfate is expected to reach a total of $2.6bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Sodium thiosulfate NPV Report.

Sodium thiosulfate is currently owned by Fennec Pharmaceuticals.

Sodium thiosulfate Overview

Sodium thiosulfate (Pedmark) is a reducing agent. It is formulated as solution for intravenous route of administration. Pedmark is indicated to reduce the risk of ototoxicity associated with cisplatin in pediatric patients 1 month of age and older with localized, non-metastatic solid tumors.

Sodium thiosulfate (STS) is under development for the prevention of cisplatin-induced ototoxicity in children. The drug candidate is administered intravenously. It is a water soluble salt and reducing agent that reacts with oxidizing agents. It is a chemoprotectant and covalently targets any residual extracellular cisplatin.

Fennec Pharmaceuticals Overview

Fennec Pharmaceuticals (Fennec) formerly Adherex Technologies Inc, develops drugs for cancer treatments. The company lead product candidate, Pedmark, anhydrous injection in two Phase III clinical trials for the prevention of cisplatin-induced hearing loss and ototoxicity in children. The company has licensing agreements with Oregon Health & Science University for development of its drug candidates. The company seeks to establish relationships with contract research organizations, universities and other institutions for development of its drug candidates. Fennec is headquartered in Durham, North Carolina, the US.

The operating loss of the company was US$17.2 million in FY2021, compared to an operating loss of US$17.9 million in FY2020. The net loss of the company was US$17.4 million in FY2021, compared to a net loss of US$18.1 million in FY2020.

Quick View – Sodium thiosulfate

Report Segments
  • Innovator (Non-NME)
Drug Name
  • Sodium thiosulfate
Administration Pathway
  • Intravenous
Therapeutic Areas
  • Ear Nose Throat Disorders
Key Companies
Highest Development Stage
  • Marketed

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.